['b-cell chronic lymphocytic leukemia']
['ibrutinib', 'erythromycin', 'voriconazole']

        Inclusion Criteria:

          -  Histologically or cytologically confirmed Chronic Lymphocytic Leukemia /Small
             Lymphocytic Lymphoma (CLL/SLL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma
             (MCL), Follicular Lymphoma (FL), or Waldenstrom's Macroglobulinemia (WM)

          -  Relapsed or refractory disease after at least 1 prior line of systemic therapy
             (participants with FL or MZL must have failed anti-CD20 monoclonal antibody containing
             chemotherapy regimen)

          -  Eastern Cooperative Oncology Group Performance Status score of 0 or 1

          -  Hematology values within the following limits: a) Absolute neutrophil count (ANC)
             greater than and equal to (>=) 1.0*10^9 per liter (L); b) Platelets >=50*10^9/L
             without transfusion support within 7 days; c) Hemoglobin >=8 gram per deciliter (g/dL)
             without transfusion support within 7 days; d) Prothrombin time /International
             normalized ratio (PT/INR) less than equal to (<=) 1.5*Upper Limit of Normal (ULN) and
             activated partial thromboplastin time (aPTT) <=1.5*ULN

          -  Biochemical values within the following limits: a) Alanine aminotransferase (ALT) and
             aspartate aminotransferase (AST) <=3.0*ULN; b) Total bilirubin <=1.5*ULN (unless due
             to Gilbert's syndrome); c) Serum creatinine <=1.5*ULN or a calculated creatinine
             clearance of >=50 milliliter per minute per 1.73 square meter

        Exclusion Criteria:

          -  Major surgery within 4 weeks of the first dose of ibrutinib

          -  Diagnosed or treated for malignancy other than the indication under study except for:
             a) Adequately treated non-melanoma skin cancer or lentigo maligna, curatively treated
             in-situ cancer without evidence of disease; b) Malignancy treated with curative intent
             and with no known active disease present for >=3 years before the first dose of
             ibrutinib

          -  History of stroke or intracranial hemorrhage within 6 months prior to the first dose
             of ibrutinib

          -  History of galactose intolerance

          -  Requires anticoagulation with warfarin or equivalent vitamin K antagonists (for
             example, phenprocoumon)
      